Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov-Dec;63(6):630-637.
doi: 10.20945/2359-3997000000193.

Determinants of morbidities and mortality in acromegaly

Leandro Kasuki  1   2   3 , Paula da Silva Rocha  1 , Elisa Baranski Lamback  1 , Mônica Roberto Gadelha  1   2   4
Affiliations
Review

Determinants of morbidities and mortality in acromegaly

Leandro Kasuki et al. Arch Endocrinol Metab. 2019 Nov-Dec.

Abstract

Acromegaly is a systemic disease associated with increased morbidity, presenting cardiovascular, metabolic, respiratory, neoplastic, endocrine, articular and bone complications. Most of these comorbidities can be prevented or delayed with adequate disease treatment and, more recent studies with the use of modern treatments of acromegaly, have shown a change in the severity and prevalence of these complications. In addition, acromegaly is associated with increased mortality, but recent studies (especially those published in the last decade) have shown a different scenario than older studies, with mortality no longer being increased in adequately controlled patients and a change in the main cause of death from cardiovascular disease to malignancy. In this review, we discuss this changing face of acromegaly summarizing current knowledge and evidence on morbimortality of the disease. Arch Endocrinol Metab. 2019;63(6):630-7.

PubMed Disclaimer

Conflict of interest statement

Disclosure: MRG has received unrestricted research grants and speaker fees from Novartis, Ipsen and Pfizer and has participated on advisory boards of Novartis and Ipsen. LK has received speaker fees from Novartis, Ipsen and Pfizer. The other authors have nothing to disclose.

Figures

Figure 1
Figure 1. Effects of acromegaly on glucose and lipid metabolism. GH: growth hormone; GLUT: glucose transporter; HDL: high-density lipoprotein; TG: triglycerides.
Figure 2
Figure 2. Effects of acromegaly in systemic arterial hypertension. SAH: systemic arterial hypertension; GH: growth hormone; IGF-I: insulin-like growth factor I.
Figure 3
Figure 3. Acromegaly cardiomyopathy.
GH: growth hormone; IGF-I: insulin-like growth factor I.
Figure 4
Figure 4. Respiratory disorders in acromegaly.
BMI: body mass index.
See this image and copyright information in PMC

References

    1. Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. Endocr Rev. 2019;40(1):268-332. - PubMed
    1. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152-77. - PubMed
    1. Frara S, Maffezzoni F, Mazziotti G, Giustina A. Current and Emerging Aspects of Diabetes Mellitus in Acromegaly. Trends Endocrinol Metab. 2016;27(7):470-83. - PubMed
    1. Vila G, Jorgensen JOL, Luger A, Stalla GK. Insulin Resistance in Patients With Acromegaly. Front Endocrinol (Lausanne). 2019;10:509. - PMC - PubMed
    1. Pratipanawatr T, Pratipanawatr W, Rosen C, Berria R, Bajaj M, Cusi K, et al. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. Am J Physiol Endocrinol Metab. 2002;282(6):E1360-8. - PubMed

LinkOut - more resources